Quantcast

Latest R207910 Stories

2011-11-30 10:50:15

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections. DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin,...

2009-06-17 08:15:00

SEATTLE, June 17 /PRNewswire/ -- When: Wednesday, June 17, 2009, 10:30am Eastern (9:30am Central; 8:30am Mountain; 7:30am Pacific) Dial-in: 1-877-879-6184 (toll-free) 1-719-325-4759 (local access) Conference Title: TB Alliance/Tibotec Briefing Participant passcode: 2895940 Where: Pacific Health Summit Bell Harbor International Conference Center Pacific Board Room Seattle,...

2009-06-17 07:00:00

Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis SEATTLE, June 17 /PRNewswire/ -- A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to...

2009-06-03 16:00:00

Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB MECHELEN, Belgium, June 3 /PRNewswire/ -- Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the addition of TMC207 for eight weeks to a 5-drug background...

2008-09-15 09:00:11

Tuberculosis drug shows promise against latent bacteria WASHINGTON, Sept. 12 (Xinhua) -- A new study has shown that an investigational drug R207910, currently in clinical trials against multi-drug resistant tuberculosis strains, is quite effective at killing latent bacteria, a report said on Friday. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease, researchers from Johnson & Johnson reported in the Sept. 12 issue...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related